A fact-finding study on the treatment of gastroesophageal reflux disease (GERD) - Prospective study on therapeutic effects of proton pump inhibitors on reflux esophagitis - - A prospective fact-finding study on the treatment of gastroesophageal reflux disease (GERD)

GERD Society0 sites120 target enrollmentStarted: March 18, 2011Last updated: October 17, 2023

Trial Snapshot

No summary available.

•1) Patients with a history of gastrointestinal resection or vagotomy 2) Patients with warning signs such as vomiting, gastrointestinal bleeding (including findings of hematemesis, melena, and anemia), or sudden weight loss 3) Patients with concurrent peptic ulcer (not in the scarring stage) 4) Patients with a prior or current history of any of the following diseases: - Zollinger-Ellison syndrome - Inflammatory bowel disease (IBD) - Irritable bowel syndrome (IBS) - Esophageal stricture - Eosinophilic reflux esophagitis - Esophageal achalasia - Malabsorption - Cerebrovascular disorders such as cerebral hemorrhage and cerebral infarction 5) Patients complicated by serious hepatic, renal, cardiac, or other diseases for which the participation in the study would be difficult 6) Patients with a confirmed or suspected malignant lesion 7) Patients who are pregnant, breastfeeding, or may be pregnant 8) Patients considered to require continued use of any drugs that could interact with the study drugs (i.e., atazanavir sulfate, diazepam, phenytoin, warfarin, tacrolimus hydrate, digoxin, methyldigoxin, itraconazole, gefitinib, voriconazole, antacids containing aluminium hydroxide gel and magnesium hydroxide, and clopidogrel) 9) Patients with a history of hypersensitivity to any components of proton pump inhibitor products 10) Patients who received a proton pump inhibitor within a week prior to endoscopy 11) Other patients judged by the physician to be inappropriate for this study

Sponsor

GERD Society